



**Developing precision
therapies for chronic
inflammation,
autoimmune
diseases and cancer**

Noxopharm (ASX:NOX)
Investor Presentation
September 2026



Disclaimer

This presentation has been prepared by Noxopharm Limited (Noxopharm, NOX or the Company). It should not be considered as an offer or invitation to subscribe for, or purchase any shares in NOX, or as an inducement to purchase any shares in NOX. No agreement to subscribe for securities in NOX will be entered into on the basis of this presentation or any information, opinions or conclusions expressed in the course of this presentation.

This presentation is not a prospectus, product disclosure document, or other offering document under Australian law or under the law of any other jurisdiction.

It has been prepared for information purposes only and is for personal use only. This presentation contains general summary information and does not take into account the investment objectives, financial situation and particular needs of an individual investor. It is not financial product advice, and the Company is not licenced to, and does not provide, financial advice.

This presentation contains forward-looking statements which are identified by words such as ‘could’, ‘believes’, ‘estimates’, ‘targets’, ‘potential’, ‘enables’, ‘expects’, ‘opportunity’ or ‘intends’ and other similar words that involve risks and uncertainties. These statements are based on an assessment of past and present economic and operating conditions, and on a number of assumptions regarding future events and actions that, as at the date of this presentation, are expected to take place.

Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors many of which are beyond the control of the Company, its Directors and management.

Although the Company believes that the expectations reflected in the forward looking statements included in this presentation are reasonable, none of the Company, its Directors or officers can give, or gives, any assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this document will actually occur or that the assumptions on which those statements are based are exhaustive or will prove to be correct beyond the date of its making. Readers are cautioned not to place undue reliance on these forward-looking statements. Except to the extent required by law, the Company has no intention to update or revise forward-looking statements, or to publish prospective financial information in the future, regardless of whether new information, future events or any other factors affect the information contained in this presentation.

Readers should make their own independent assessment of the information and take their own independent professional advice in relation to the information and any proposed action to be taken on the basis of the information. To the maximum extent permitted by law, the Company and its professional advisors and their related bodies corporate, affiliates and each of their respective directors, officers, management, employees, advisers and agents and any other person involved in the preparation of this presentation disclaim all liability and responsibility (including without limitation and liability arising from fault or negligence) for any direct or indirect loss or damage which arise or be suffered through use of or reliance on anything contained in, or omitted from, this presentation. Neither the Company nor its advisors have any responsibility or obligation to update this presentation or inform the reader of any matter arising or coming to their notice after the date of this presentation document which affect any matter referred to in the presentation.

SOF-SKN™, SOF-CAN™ and SOF-VAC™ are currently not approved for use in Australia or any other country.

Noxopharm and its SOF-CAN and SOF-VAC programs do not have any relationship with the INTERpath-001 trial.

Noxopharm – Harnessing the immune system to fight disease

NOXOPHARM

Australian clinical-stage biotechnology company developing *novel targeted immuno-therapies* for chronic inflammation, autoimmune diseases and cancer

Proprietary Sofra™ platform

- Built upon a newly discovered role of natural RNA (Ribonucleic Acid) in controlling the immune system
- Sofra produces targeted immuno-therapies that replicate this role using synthetic RNA-based molecules (oligonucleotides)*


Lead asset: SOF-SKN™

- Successfully completed FIH clinical trial
- Upcoming extension study in cutaneous lupus erythematosus (CLE) patients Q1 2027 to provide efficacy data ahead of Phase 2 clinical trial

Broader platform potential

- Pursuing autoimmunity, oncology, mRNA (messaging RNA) vaccines
- INTerpath-001 Phase 3 data by Moderna/Merck strengthens the potential of Noxopharm's mRNA vaccine enhancement and oncology approaches

*Validated in *Nature Immunology* (February 2026) and IP protected (four core patent families)



Our platform

NOXOPHARM

Developing proprietary synthetic RNA-based medicines (oligonucleotides)



>50% of all deaths are linked to inflammation¹



Market opportunity for precise, targeted therapies in place of broad immune suppression



OUR SOLUTION


The Sofra™ Tech Platform

Turning natural RNA immune control into **targeted therapeutics** using **synthetic RNA** oligonucleotides



AUTOIMMUNE DISEASES / INFLAMMATION

Innovative drugs for diseases related to inflammation and autoimmunity, which are growing worldwide.



IMMUNO-ONCOLOGY

New technology for a rapidly growing area of cancer treatment characterised by best-selling drugs in globally significant markets.



mRNA VACCINE ADJUVANCY

Supporting the delivery of new mRNA vaccines as the industry extends beyond the COVID era.

¹ Furman, D. et al. Nat Med. 2019, 25: 1822–1832.

How does Sofra technology work?


NOXOPHARM

Translating naturally occurring immune-control into targeted medicines

1

Nature's off-switch discovery

Natural RNA fragments help keep innate immune receptors inactive




This natural system prevents the immune system for reacting to itself

2

Sofra decodes it from natural RNA

Noxopharm has identified RNA control codes for individual immune receptors




These act as natural 'off-switches' for immune receptors.

3

Sofra encoded RNA medicines

Control code encoded into oligonucleotide for targeted activity



This synthetic RNA allows precision control across selected receptors

4

Application potential across therapeutic areas



Autoimmune diseases / Inflammation



RNA therapeutics and vaccines



Cancer

Enabled by proprietary modulators of TLR3/7/8/9, cGAS and RIG-I

A strong and diverse pipeline

NOXOPHARM

A single technology platform supporting multiple immuno-therapy approaches

	Program	Focus	MoA	Partner	Discovery	PoC	IND-enabling	Clinical
 Autoimmune diseases / Inflammation	SOF-SKN™ Lead asset	Topical therapy; initial focus on cutaneous lupus erythematosus (CLE)	TLR7/8	Internal	Phase I complete; Phase II preparation			
	SOF-16™ SOF-SKN™ active	Systemic / inhalable therapy – inflammatory lung diseases · rheumatoid arthritis · diabetes	TLR7/8	InhaTarget · Tezcat · BioRay	In vivo PoC / Discovery			
 Immuno-oncology	SOF-CAN™ Cancer program	Amplifies immune detection of tumor RNA; combinable with PD-1 checkpoint inhibitors	TLR8 Amplifier	Internal	Lead optimisation			
 mRNA therapeutics	SOF-VAC™ RNA therapeutic enhancement	Reduces reactogenicity / broaden dosing window of mRNA vaccines	RIG-I · TLR7 + others	CSL+ Undisclosed	In vivo PoC			


Clinical-stage SOF-SKN anchors a broader pipeline of partnered and platform-derived opportunities

Near-term milestones and catalysts

NOXOPHARM

Multiple potential value drivers over the next 12 months

Next 12 months



A series of clinical, preclinical, regulatory and partnership milestones with the potential to drive value

Lead asset and clinical progress



AUTOIMMUNE DISEASES /
INFLAMMATION

SOF-SKN innovation at a glance

NOXOPHARM

Lead clinical asset for cutaneous lupus erythematosus (CLE)

What is Lupus?



An autoimmune disease that can affect different organs.



Cutaneous lupus erythematosus (CLE) manifests in the skin.



Unmet need for well tolerated targeted therapies.



SOF-SKN is a topical clinical stage candidate.

SOF-SKN Clinical Pipeline

- 1 Phase I (HERACLES) complete in healthy volunteers:** favourable safety profile.
- 2 Extension Study in CLE patients to commence — Q1 2027:** targeting initial efficacy signals alongside further safety and tolerability data
- 3 Phase II planning underway:** targeted for H1 2028, Pre-IND meeting with FDA and GMP manufacturing in progress
- 4 Further expansion** into adjacent inflammatory skin indications beyond CLE.

Targeting global dermatology markets


NOXOPHARM

Initial focus on CLE valued at US\$5.4 billion (2024) with no current targeted therapies

Potential expansion into adjacent inflammatory skin diseases

Selected inflammatory skin disease TAM

~US\$43B (2025E) → ~US\$56B (2034F)



SOF-SKN is positioned for focused CLE entry before expansion across broader inflammatory skin disease markets

SOF-SKN: mechanism of action

NOXOPHARM

Targeting overactive TLR7/8 signalling at the source of skin inflammation



Overactive immune receptors Toll-like receptors 7 and 8 (TLR7/8) can drive inflammatory skin diseases



SOF-SKN is applied directly to affected skin



Its active ingredient, SOF-16, is designed to inhibit TLR7/8 signalling





Targeted approach to reduce inflammatory signalling locally while limiting systemic exposure



TLR7/8 is a clinically validated target for lupus



In Vivo Efficacy Demonstrated



Aldara model, mouse

Significant reduction in skin inflammation vs vehicle



Reduced redness



Reduced scaliness

Favourable Delivery Profile



Prolonged skin retention
Skin half-life of approx. 3.5 days in preclinical studies



Localised exposure
Localised skin exposure with no systemic exposure observed in the clinical studies

The SOF-SKN competitive advantage

NOXOPHARM

How SOF-SKN compares on clinical stage, mechanism, safety and durability

	Approved CLE Therapies Kenalog / Plaquenil	Emerging oral TLR7/8 inhibitors Enpatoran (Merck) / Afimetoran (BMS)	SOF-SKN Topical TLR7/8 Inhibitor
 Clinical stage	In market	Phase II / Phase III	Phase I
 Targeted mechanism	✗	✓	✓
 Route of administration	Injectable/Oral	Oral	Topical
 Safety profile (reported)	Established systemic side effects	Generally well tolerated (respiratory infections)	Favourable profile to date
 Minimised systemic immune suppression	✗	✗	✓
 Prolonged targeted retention	✗	✗	✓


SOF-SKN combines targeted immune modulation with localised delivery to minimise systemic exposure

Progressive clinical trial strategy


NOXOPHARM

Accelerating SOF-SKN's clinical development in patients with CLE

Extension Study




Phase II trial



Platform opportunities



mRNA VACCINE
ADJUVANCY



IMMUNO-
ONCOLOGY

SOF-VAC and SOF-CAN use the same underlying oligonucleotide technology

Sofra Platform

Encoding immune control into synthetic RNA oligonucleotides allows precision tuning of the immune system in two directions



Targeted immune **inhibition**




mRNA VACCINE ADJUVANCY

SOF-VAC

Enhancing mRNA vaccines
by limiting side effects



Targeted immune **activation**



IMMUNO-ONCOLOGY

SOF-CAN

Selective activation of
immune system to fight cancer




SOF-VAC - Enhancing mRNA medicines and vaccines

NOXOPHARM

Designed to limit side effects of mRNA vaccines


SOF-VAC - mechanism of action

mRNA vaccine



mRNA vaccine fragments bind to inflammatory receptors in the body (called TLR7) causing overstimulation which results in inflammation, and other vaccine side-effects e.g. fever, muscle ache and fatigue.

mRNA vaccine with SOF-VAC™



When SOF-VAC is combined with the mRNA vaccine, it blocks the inflammation receptors and reduces vaccine side-effects.

Key advantages

- Reduces off-target reactogenic side effects of mRNA vaccines
- Enables potential for higher mRNA doses, increasing efficacy while maintaining safety
- Sofra RNA technology allows targeted activity for one or multiple immune receptors tailored to each mRNA vaccine

Current progress - validated approach

Targeting RIG-I

CSL present positive preclinical results - SOF-VAC in conjunction with sa-mRNA


Presented by CSL in September 2026 at the Washington Options XIII Conference for the Control of Influenza

Targeting TLR7

In vivo proof-of-concept with mRNA published in *Nature Immunology* (2026)

<https://www.nature.com/articles/s41590-026-02429-2>

Ongoing development - through external collaborations



SOF-CAN - Precision immune activation to fight cancer

NOXOPHARM

Precision immune activation for next-generation cancer immunotherapy

How SOF-CAN works and key advantages

- Toll-like receptor 8 (TLR8) in immune cells plays an important role in alerting the immune system to threats
- But cancer usually avoids detection by TLR8
- SOF-CAN employs a synthetic RNA molecule (TLR8 amplifier) that allows TLR8 to detect the cancer's presence
- This **unmasking of cancer** to TLR8 enables a controlled immune activation directed selectively towards cancer cells
- SOF-CAN has potential as monotherapy or in combination for improved patient outcomes across multiple types of cancer

Current progress




Ex vivo proof-of-concept announced, R&D at late-stage lead optimisation



In vivo study prepped for lead candidate selection towards IND-enabling studies

SOF-CAN - mechanism of action



Multiple opportunities in mRNA vaccines and immuno-oncology

NOXOPHARM

SOF-VAC and SOF-CAN use the same underlying oligonucleotide technology

Technologies supporting **higher, safer doses** of mRNA



mRNA VACCINE ADJUVANCY SOF-VAC USE CASES

Can enhance mRNA and other RNA vaccines for:

- COVID + future pandemics
- Flu
- Cancer
- New vaccines for other diseases

Technologies selectively **activating** the immune system



IMMUNO-ONCOLOGY SOF-CAN USE CASES

Adaptable designed Cancer-fighting technology:

- Multiple cancer types
- Monotherapy and combination potential with
 - Chemotherapies and Radiotherapies
 - Checkpoint inhibitors
 - New mRNA cancer vaccines

Addresses Gaps in Growing Markets

- mRNA therapies **US\$26B** (2034E)
- Immuno-oncology **US\$185B** (2035E)
- Top selling immuno-oncology drug Keytruda **US\$31.7B** in 2025
- **Moderna / Merck trials show power of mRNA vaccines + immuno-oncology**

Noxopharm Progress + Next Steps

- **Independent SOF-VAC validation via CSL project**
 - Next step: Further develop external partnerships
- **Promising results from ex vivo SOF-CAN studies**
 - Next steps: *In vivo* proof-of-concept studies + select clinical candidate

Moderna-Merck INTERpath-001 Phase 3 trial data (reported 19 August 2026) validates mRNA neoantigen vaccine as a new therapeutic approach in immuno-oncology (intismeran autogene) + KEYTRUDA® vs. KEYTRUDA® alone, in resected stage IIB–IV melanoma.

Comprehensive IP strategy

NOXOPHARM

A growing patent portfolio supporting the Sofra platform and lead programs



Long-term collaboration with Hudson Institute of Medical Research (HIMR) enabling ongoing research that underpins the Sofra platform.



Key HIMR collaboration discoveries were **exclusively licensed** to Noxopharm in **2021**. Four core patent families owned by Noxopharm, with standard milestone and royalty payments upon late-stage clinical development and commercial sales.



FOUR CORE SOFRA PATENT FAMILIES

Covering oligonucleotides that modulate TLR7 and/or TLR8 activity, plus RIG-I inhibition and other innate immune sensors



BROAD INTERNATIONAL COVERAGE

Patent protection extends across key international markets including the US, Australia, Europe, Canada, China, Japan and Korea



FIRST US SOFRA PATENT GRANTED

First US Sofra patent granted, covering oligonucleotides that potentiate TLR8 activity



ADDITIONAL US CONTINUATION APPLICATION FILED

Additional US continuation application filed to pursue cancer-treatment methods using the patented oligonucleotides



SOF-SKN FORMULATION PROTECTION

Dedicated patent protection for the SOF-SKN topical formulation and methods of treating inflammatory skin diseases



POTENTIAL PROTECTION INTO THE 2040s

Core Sofra patent families have potential protection extending into the 2040s, subject to jurisdiction and applicable patent-term extensions

Experienced Management Team

NOXOPHARM



Dr Olivier Laczka

CEO

BSc, MSc, PhD

Experienced biotechnology and drug development executive with expertise spanning research and academia, intellectual property, funding and international collaborations.



Shawn van Boheemen

CFO

BBus MCom, FCPA, JP

30 years' commercial finance leadership experience across healthcare, biotechnology, manufacturing and financial services. Strong background in ASX, ASIC and SEC reporting, compliance, audit and taxation.



Dr Daniel Wenholtz

Director of Pharmaceutical Chemistry

BSc, PhD

Experience across academia and the pharmaceutical industry, and a key contributor to development of the Sofra platform. Expertise includes drug discovery, analytical science and the design and synthesis of oligonucleotides and small molecules.

Expert Scientific Advisory Board



Prof Michael Gantier

Professor, Research Group Head, Nucleic Acids and Innate Immunity, Hudson Institute of Medical Research

More than 20 years' experience in RNA biology and innate immunity. Research has uncovered mechanisms regulating immune responses, including critical foundational work underpinning the Sofra platform. Has published over 85 papers and is Associate Editor of *Molecular Therapy Nucleic Acids*.



Prof Marcel Nold

Professor of Paediatric Immunology and Consultant Neonatal Paediatrician, Monash University

Consultant neonatologist and also clinician-scientist at Hudson Institute. Research focuses on interventional immunology, anti-inflammatory cytokines and translational therapies for autoimmune and inflammatory disease. Has published more than 70 peer-reviewed papers.



Prof Naresh Kumar

Professor, School of Chemistry, UNSW Sydney

Professor of Organic and Medicinal Chemistry with extensive expertise in the design and synthesis of bioactive molecules, medicinal chemistry and biomaterials. Significant industry collaboration and commercialisation experience. Inventor on 27 patents and has published around 290 research papers.



A/Prof Amanda Saracino

A/Prof University College London, Connective Tissue Disease clinic founder and lead, St Vincent's Hospital

Dermatologist specialising in autoimmune connective tissue diseases. Leads dermatology connective tissue disease clinic at St Vincent's Hospital Melbourne, with research focused on lupus erythematosus, scleroderma and targeted therapies for autoimmune skin disease.

Investment highlights

NOXOPHARM

Clinical progress, platform potential and multiple value-driving catalysts


- **Clinical-stage lead asset:** SOF-SKN has completed Phase I in healthy volunteers, with an extension study to include CLE patients in final preparation and Phase II planning underway.
- **Unique platform with broad potential:** Sofra supports the development of therapeutics across:



AUTOIMMUNE DISEASES /
INFLAMMATION



mRNA VACCINE
ADJUVANCY



IMMUNO-ONCOLOGY

- **Scientific validation and external collaboration:** Scientific collaborations and external development programs support broader platform development and a diversified pipeline.
- **Near-term catalysts:** Multiple clinical, non-clinical, regulatory, manufacturing, scientific and partnering milestones expected over the next 12 months.

Corporate overview


Key corporate and market information

ASX code:	NOX
GICS classification:	Pharmaceuticals, Biotechnology & Life Sciences
Latest share price:	\$0.089 (as at 01/09/26)
Market capitalisation	\$27.03M
Shares on issue ¹ :	307,237,950
52-week high:	\$0.135
52-week low:	\$0.051
Average daily trading volume:	180,023

1. Excludes 3.85 million convertible notes on issue convertible at AU\$0.992 on or before 02 January 2027

NOXOPHARM

Shareholding Split



12-month share price performance





Noxopharm (ASX:NOX)

For more information, please contact:

Dr Olivier Laczka

Chief Executive Officer

E: Olivier.laczka@noxopharm.com

P: +61 2 9144 2223

Gaby Hold

The Capital Network

E: gaby@thecapitalnetwork.com.au

P: +61 2 7257 7338



Website:

www.noxopharm.com

